Deutsche Bank AG Has $348.11 Million Stake in Elevance Health, Inc. (NYSE:ELV)

Deutsche Bank AG boosted its position in Elevance Health, Inc. (NYSE:ELV) by 5.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 943,632 shares of the company’s stock after buying an additional 50,220 shares during the quarter. Deutsche Bank AG owned approximately 0.41% of Elevance Health worth $348,106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently bought and sold shares of ELV. Principal Financial Group Inc. lifted its position in Elevance Health by 4.5% in the third quarter. Principal Financial Group Inc. now owns 272,649 shares of the company’s stock valued at $141,777,000 after purchasing an additional 11,646 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Elevance Health by 3.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 21,166 shares of the company’s stock valued at $7,808,000 after buying an additional 739 shares in the last quarter. ST Germain D J Co. Inc. lifted its holdings in shares of Elevance Health by 56.3% in the fourth quarter. ST Germain D J Co. Inc. now owns 1,322 shares of the company’s stock worth $488,000 after buying an additional 476 shares in the last quarter. Czech National Bank increased its holdings in shares of Elevance Health by 6.5% in the fourth quarter. Czech National Bank now owns 50,286 shares of the company’s stock worth $18,551,000 after purchasing an additional 3,049 shares during the last quarter. Finally, Fiduciary Alliance LLC lifted its position in Elevance Health by 701.9% during the fourth quarter. Fiduciary Alliance LLC now owns 4,956 shares of the company’s stock valued at $1,828,000 after purchasing an additional 4,338 shares during the last quarter. 89.24% of the stock is owned by institutional investors.

Insider Buying and Selling at Elevance Health

In related news, CAO Ronald W. Penczek sold 443 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $415.13, for a total transaction of $183,902.59. Following the sale, the chief accounting officer now owns 1,847 shares of the company’s stock, valued at $766,745.11. This trade represents a 19.34 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $396.30, for a total value of $1,388,635.20. Following the completion of the sale, the executive vice president now owns 10,116 shares in the company, valued at $4,008,970.80. This trade represents a 25.73 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,535 shares of company stock valued at $3,521,612. Corporate insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $478.00 price objective on shares of Elevance Health in a research note on Wednesday, April 23rd. Truist Financial lifted their price objective on shares of Elevance Health from $480.00 to $510.00 and gave the stock a “buy” rating in a research report on Friday, April 11th. StockNews.com upgraded shares of Elevance Health from a “hold” rating to a “buy” rating in a research note on Thursday, March 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $485.00 target price on shares of Elevance Health in a report on Wednesday, April 23rd. Finally, Robert W. Baird reissued a “neutral” rating and issued a $529.00 price target (down from $625.00) on shares of Elevance Health in a report on Tuesday, April 15th. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $510.38.

Elevance Health Stock Down 1.1 %

ELV stock opened at $413.01 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. Elevance Health, Inc. has a 1-year low of $362.21 and a 1-year high of $567.26. The firm has a fifty day moving average price of $424.00 and a two-hundred day moving average price of $404.69. The firm has a market cap of $93.31 billion, a price-to-earnings ratio of 16.13, a PEG ratio of 1.18 and a beta of 0.66.

Elevance Health (NYSE:ELV) last announced its earnings results on Tuesday, April 22nd. The company reported $11.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.60 by $1.37. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. The company had revenue of $48.77 billion for the quarter, compared to analyst estimates of $46.26 billion. Research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Tuesday, June 10th will be issued a dividend of $1.71 per share. This represents a $6.84 dividend on an annualized basis and a yield of 1.66%. The ex-dividend date of this dividend is Tuesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 26.69%.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.